LATANOPROST

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C26H40O5
Molecular Weight	432.5928
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC2=CC=CC=C2

InChI

InChIKey=GGXICVAJURFBLW-CEYXHVGTSA-N

InChI=1S/C26H40O5/c1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b8-3-/t21-,22+,23+,24-,25+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C26H40O5
Molecular Weight	432.5928
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 5
E/Z Centers	1
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9698288 | https://www.ncbi.nlm.nih.gov/pubmed/21788077http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020597s045s048lbl.pdfhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207795Orig1s000lbl.pdf
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/29194198 | https://clinicaltrials.gov/ct2/show/NCT01895972 | https://www.ncbi.nlm.nih.gov/pubmed/28783422 | https://clinicaltrials.gov/ct2/show/NCT01749904

Latanoprostene Bunod (LBN) is a topical ophthalmic therapeutic for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. There is no cure for glaucoma and therapeutic management is predominantly focused on minimizing disease progression and clinical sequelae via the reduction and maintenance of appropriate target IOPs. Latanoprostene Bunod is thought to lower intraocular pressure via a dual mechanism of action since the medication is metabolized into two relevant moieties upon administration: latanoprost acid, and butanediol mononitrate. As a prostaglandin F2-alpha analog, the latanoprost acid moiety operates as a selective PGF2-alpha (FP) receptor agonist. Since FP receptors occur in the ciliary muscle, ciliary epithelium, and sclera the latanoprost acid moiety primarily acts in the uveoscleral pathway where it increases the expression of matrix metalloproteinases (MMPs) like MMP-1, -3, and -9 which promote the degradation of collagen types I, III, and IV in the longitudinal bundles of the ciliary muscle and surrounding sclera. The resultant extracellular matrix remodeling of the ciliary muscle consequently produces reduced outflow resistance via increased permeability and increased aqueous humor outflow through the uveoscleral route. Conversely, the butanediol mononitrate undergoes further metabolism to NO and an inactive 1,4-butanediol moiety. As a gas that can freely diffuse across plasma membranes, it is proposed that the relaxing effect of NO to induce reductions in the cell volume and contractility of vascular smooth muscle-like cells is dependent upon activation of the sGC/cGMP/PKG cascade pathway. NO released from butanediol mononitrate consequently enters the cells of the TM and an inner wall of SC, causing decreases in myosin light chain-2 phosphorylation, increased phosphorylation of large-conductance calcium-activated potassium (BKCa) channels, and a subsequent efflux of potassium ions through such BKCa channels. All of these changes serve to decrease the cell contractility and volume, as well as to rearrange the actin cytoskeleton of the TM and SC cells. These biomechanical changes ultimately allow for enhanced conventional outflow of aqueous humor.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Prostaglandin F2-alpha receptor 12 Target ID: P43088 Gene ID: 5737.0 Gene Symbol: PTGFR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/10634944	Agonist 2637	3.6 nM [EC50]
Prostanoid FP receptor 23 Target ID: CHEMBL1987 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9733584	Agonist 2637
Prostanoid FP receptor 23 Target ID: CHEMBL1987 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207795Orig1s000lbl.pdf	Agonist 2637

Conditions

Condition	Modality	Highest Phase	Product
Open-angle glaucoma 50 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207795Orig1s000lbl.pdf	Primary	Approved 8307	VYZULTA Approved Use VYZULTA is a prostaglandin analog indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension Launch Date 1.48668482E12
Ocular hypertension 49 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207795Orig1s000lbl.pdf	Primary	Approved 8307	VYZULTA Approved Use VYZULTA is a prostaglandin analog indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension Launch Date 1.48668482E12
Open-angle glaucoma 50 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207795Orig1s000lbl.pdf	Primary	Approved 8307	VYZULTA Approved Use YZULTA™ (latanoprostene bunod ophthalmic solution) 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Launch Date 1.50949436E12
Ocular hypertension 49 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207795Orig1s000lbl.pdf	Primary	Approved 8307	VYZULTA Approved Use YZULTA™ (latanoprostene bunod ophthalmic solution) 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Launch Date 1.50949436E12
Open-angle glaucoma 50 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020597s045s048lbl.pdf	Palliative	Approved 8307	XALATAN Approved Use XALATAN Sterile Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Launch Date 8.3393282E11
Ocular hypertension 49 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020597s045s048lbl.pdf	Primary	Approved 8307	XALATAN Approved Use XALATAN Sterile Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Launch Date 8.3393282E11

C_max

Value	Dose	Co-administered	Analyte	Population
53 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12204697/	1.5 μg single, ocular dose: 1.5 μg route of administration: Ocular experiment type: SINGLE co-administered:		LATANOPROST ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
7.15 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12204697/	3 μg/kg bw single, intravenous dose: 3 μg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered:		LATANOPROST ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
34 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12204697/	1.5 μg single, ocular dose: 1.5 μg route of administration: Ocular experiment type: SINGLE co-administered:		LATANOPROST ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
16.6 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12204697/	3 μg/kg bw single, intravenous dose: 3 μg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered:		LATANOPROST ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
17 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12204697/	1.5 μg single, ocular dose: 1.5 μg route of administration: Ocular experiment type: SINGLE co-administered:		LATANOPROST ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.005 % 1 times / day multiple, topical Recommended Dose: 0.005 %, 1 times / day Route: topical Route: multiple Dose: 0.005 %, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206185Orig1s000StatR.pdf	unhealthy, mean age 63.1 years n = 289 Health Status: unhealthy Condition: open-angle glaucoma \| ocular hypertension Age Group: mean age 63.1 years Sex: M+F Population Size: 289 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206185Orig1s000StatR.pdf	Disc. AE: Iritis, Meibomianitis... AEs leading to discontinuation/dose reduction: Iritis (grade 2, 0.3%) Meibomianitis (grade 1, 0.3%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206185Orig1s000StatR.pdf
11 ug/kg multiple, topical MTD Dose: 11 ug/kg Route: topical Route: multiple Dose: 11 ug/kg Sources: https://www.ema.europa.eu/en/documents/referral/xalatan-article-29-paediatrics-chmp-assessment-report_en.pdf	unhealthy Health Status: unhealthy Sources: https://www.ema.europa.eu/en/documents/referral/xalatan-article-29-paediatrics-chmp-assessment-report_en.pdf	Sources: https://www.ema.europa.eu/en/documents/referral/xalatan-article-29-paediatrics-chmp-assessment-report_en.pdf
10 ug/kg single, intravenous (max) Overdose Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020597s052lbl.pdf	healthy Health Status: healthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020597s052lbl.pdf	Other AEs: Abdominal pain, Dizziness... Other AEs: Abdominal pain Dizziness Fatigue Hot flushes Nausea Sweating Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020597s052lbl.pdf

AEs

AE	Significance	Dose	Population
Meibomianitis	grade 1, 0.3% Disc. AE	0.005 % 1 times / day multiple, topical Recommended Dose: 0.005 %, 1 times / day Route: topical Route: multiple Dose: 0.005 %, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206185Orig1s000StatR.pdf	unhealthy, mean age 63.1 years n = 289 Health Status: unhealthy Condition: open-angle glaucoma \| ocular hypertension Age Group: mean age 63.1 years Sex: M+F Population Size: 289 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206185Orig1s000StatR.pdf
Iritis	grade 2, 0.3% Disc. AE	0.005 % 1 times / day multiple, topical Recommended Dose: 0.005 %, 1 times / day Route: topical Route: multiple Dose: 0.005 %, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206185Orig1s000StatR.pdf	unhealthy, mean age 63.1 years n = 289 Health Status: unhealthy Condition: open-angle glaucoma \| ocular hypertension Age Group: mean age 63.1 years Sex: M+F Population Size: 289 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206185Orig1s000StatR.pdf
Abdominal pain		10 ug/kg single, intravenous (max) Overdose Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020597s052lbl.pdf	healthy Health Status: healthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020597s052lbl.pdf
Dizziness		10 ug/kg single, intravenous (max) Overdose Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020597s052lbl.pdf	healthy Health Status: healthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020597s052lbl.pdf
Fatigue		10 ug/kg single, intravenous (max) Overdose Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020597s052lbl.pdf	healthy Health Status: healthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020597s052lbl.pdf
Hot flushes		10 ug/kg single, intravenous (max) Overdose Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020597s052lbl.pdf	healthy Health Status: healthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020597s052lbl.pdf
Nausea		10 ug/kg single, intravenous (max) Overdose Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020597s052lbl.pdf	healthy Health Status: healthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020597s052lbl.pdf
Sweating		10 ug/kg single, intravenous (max) Overdose Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020597s052lbl.pdf	healthy Health Status: healthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020597s052lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP450 25	CYP 252 OATP2B1 103 MRP1 102 MRP2 196 MRP5 39 P-gp 1491 BCRP 545	CYP450 32

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP450 41	inducer 1515 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020597Orig1s000rev.pdf#page=342 Page: 342.0	unlikely
CYP450 41	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020597Orig1s000rev.pdf#page=342 Page: 342.0	unlikely

Drug as victim

Target	Modality	Activity
CYP 252	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207795Orig1s000ClinPharmR.pdf#page=9 Page: 9.0	no
P-gp 1491	substrate 3264 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096535/	no
BCRP 545	substrate 3264 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096535/	unlikely
OATP2B1 103	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/20019365/ Page: 6.0	weak
MRP1 102	substrate 3264 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096535/	yes
MRP2 196	substrate 3264 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096535/	yes
MRP5 39	substrate 3264 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096535/	yes

Sourcing

Vendor/Aggregator	ID	URL
AA Blocks	AA00BXFY	https://www.aablocks.com/goods/Goods/detail?id=AA00BXFY
AK Scientific, Inc. (AKSCI)	Z6154	http://www.aksci.com/item_detail.php?cat=Z6154
Aaron Chemicals	AR00BY7Q	http://www.aaronchem.com/41639-83-2
Achemtek	0104-022891	http://www.achemtek.com/41639-83-2
Alfa Chemistry	AP41639832-B	https://reagents.alfa-chemistry.com/product/latanoprost-acid-cas-41639-83-2-11265.html
Alfa Chemistry	AP41639832-A	https://reagents.alfa-chemistry.com/product/latanoprost-related-compound-e-cas-41639-83-2-11264.html
Ambinter	Amb15690628	http://www.ambinter.com/reference/15690628
Aurora Fine Chemicals LLC	A17.898.261	http://online.aurorafinechemicals.com/info?ID=A17.898.261
AvaChem Scientific	2038	http://www.avachem.com/productSearch.asp?2038
Chem Scene	CS-0068357	http://www.chemscene.com/41639-83-2.html
ChemMol	99087782	http://www.chemmol.com/chemmol/99087782.html
Chemspace	CSSB00020648370	https://chem-space.com/CSSB00020648370
Glentham Life Sciences	GL6689	http://www.glentham.com/products/product/GL6689/
Lab Network	LN01304996	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01304996
MedChem Express	HY-113756A	https://www.medchemexpress.com/latanoprost-acid.html
OChem	18671	http://www.ocheminc.com/index.php?act=psearch&pid=639L832
Sigma-Aldrich	L1292_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/l1292?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	1357533_USP	https://www.sigmaaldrich.com/catalog/product/usp/1357533?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S532544	http://www.smolecule.com/products/s532544
THE BioTek	bt-272608	https://www.thebiotek.com/product/inhibitors/bt-272608
eNovation Chemicals	D592348	https://www.enovationchem.com/ProductDetails.asp?ProductID=D592348
eNovation Chemicals	D758325	https://www.enovationchem.com/ProductDetails.asp?ProductID=D758325
iChemical	EBD26372	http://www.ichemical.com/products/41639-83-2.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs

PubMed

Title	Date	PubMed
The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.	2000 Jan 17	10634944
[Increased iris pigmentation after use of latanoprost in Japanese brown eyes].	2001 May	11406947
Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy.	2002 Jan	11755835
Prospective comparative switch study from timolol 0.5% and latanoprost 0.005% to bimatoprost 0.03%.	2006 Jan-Feb	16644608
24-Hour control with a latanoprost-timolol fixed combination vs timolol alone.	2006 Nov	17102001
A comparison of latanoprost monotherapy with a combination therapy of timolol/dorzolamide in patients with primary open-angle glaucoma.	2006 Summer	17416939
Latanoprost-related transient incontinence.	2007 May-Jun	17539800
Efficacy and safety of latanoprost versus pilocarpine/timolol maleate fixed combination in patients with primary open-angle glaucoma or ocular hypertension.	2008 Dec	18721251
The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost.	2010 May	20019365

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

The mechanism of prostaglandin E2-, prostaglandin F2alpha- and latanoprost acid-induced relaxation of the rabbit submental vein was studied. Both prostaglandin F2alpha and the relatively selective FP receptor agonist, latanoprost acid, caused relaxation of the veins to about 50% of the precontracted state in the presence of GR 32191B, a thromboxane receptor antagonist (EC50: for prostaglandin F2alpha 7.9 x 10(-9) M, and for latanoprost acid 4.9 x 10(-9) M).

Substance Class	Chemical Created by `admin` on `Fri Dec 16 17:45:58 UTC 2022` Edited by `admin` on `Fri Dec 16 17:45:58 UTC 2022`
Record UNII	6Z5B6HVF6O
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LATANOPROST

Official Name

English

Isopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoate

Systematic Name

English

PHXA41

Code

English

LATANOPROST [MART.]

Common Name

English

5-HEPTENOIC ACID, 7-(3,5-DIHYDROXY-2-(3-HYDROXY-5-PHENYLPENTYL)CYCLOPENTYL)-1-METHYLETHYL ESTER, (1R-(1.ALPHA.(Z),2.BETA.(R*),3.ALPHA.,5.ALPHA.))-

Common Name

English

XA-41

Code

English

T2345

Code

English

T-2345

Code

English

LATANOPROST [ORANGE BOOK]

Common Name

English

latanoprost [INN]

Common Name

English

XELPROS

Brand Name

English

Latanoprost [WHO-DD]

Common Name

English

LATANOPROST COMPONENT OF ROCKLATAN

Common Name

English

XALATAN

Brand Name

English

LATANOPROST [MI]

Common Name

English

ROCKLATAN COMPONENT LATANOPROST

Common Name

English

LATANOPROST (ISOPROPYL ESTER)

Common Name

English

LATANOPROST [USAN]

Common Name

English

LATANOPROST [JAN]

Common Name

English

XA41

Code

English

LATANOPROST [USP-RS]

Common Name

English

LATANOPROST [EP MONOGRAPH]

Common Name

English

LATANOPROST [USP MONOGRAPH]

Common Name

English

LATANOPROST [VANDF]

Common Name

English

PHXA-41

Code

English

XALACOM COMPONENT LATANOPROST

Brand Name

English

Classification Tree Code System Code

WHO-VATC

QS01EE01

Created by admin on Fri Dec 16 17:45:59 UTC 2022 , Edited by admin on Fri Dec 16 17:45:59 UTC 2022

NDF-RT

N0000007706

Created by admin on Fri Dec 16 17:45:59 UTC 2022 , Edited by admin on Fri Dec 16 17:45:59 UTC 2022

NCI_THESAURUS

C29705

Created by admin on Fri Dec 16 17:45:59 UTC 2022 , Edited by admin on Fri Dec 16 17:45:59 UTC 2022

WHO-ATC

S01EE01

Created by admin on Fri Dec 16 17:45:58 UTC 2022 , Edited by admin on Fri Dec 16 17:45:58 UTC 2022

NDF-RT

N0000007706

Created by admin on Fri Dec 16 17:45:59 UTC 2022 , Edited by admin on Fri Dec 16 17:45:59 UTC 2022

NDF-RT

N0000175454

Created by admin on Fri Dec 16 17:45:59 UTC 2022 , Edited by admin on Fri Dec 16 17:45:59 UTC 2022

NCI_THESAURUS

C78568

Created by admin on Fri Dec 16 17:45:59 UTC 2022 , Edited by admin on Fri Dec 16 17:45:59 UTC 2022

NDF-RT

N0000007706

Created by admin on Fri Dec 16 17:45:59 UTC 2022 , Edited by admin on Fri Dec 16 17:45:59 UTC 2022

Code System Code Type Description

DAILYMED

6Z5B6HVF6O

Created by admin on Fri Dec 16 17:45:58 UTC 2022 , Edited by admin on Fri Dec 16 17:45:58 UTC 2022

PRIMARY

EPA CompTox

DTXSID1041057

Created by admin on Fri Dec 16 17:45:58 UTC 2022 , Edited by admin on Fri Dec 16 17:45:58 UTC 2022

PRIMARY

USAN

II-6

Created by admin on Fri Dec 16 17:45:59 UTC 2022 , Edited by admin on Fri Dec 16 17:45:59 UTC 2022

PRIMARY

LACTMED

Latanoprost

Created by admin on Fri Dec 16 17:45:58 UTC 2022 , Edited by admin on Fri Dec 16 17:45:58 UTC 2022

PRIMARY

ChEMBL

CHEMBL1051

Created by admin on Fri Dec 16 17:45:58 UTC 2022 , Edited by admin on Fri Dec 16 17:45:58 UTC 2022

PRIMARY

CHEBI

6384

Created by admin on Fri Dec 16 17:45:58 UTC 2022 , Edited by admin on Fri Dec 16 17:45:58 UTC 2022

PRIMARY

INN

6980

Created by admin on Fri Dec 16 17:45:58 UTC 2022 , Edited by admin on Fri Dec 16 17:45:58 UTC 2022

PRIMARY

MESH

C072042

Created by admin on Fri Dec 16 17:45:58 UTC 2022 , Edited by admin on Fri Dec 16 17:45:58 UTC 2022

PRIMARY

NCI_THESAURUS

C29151

Created by admin on Fri Dec 16 17:45:58 UTC 2022 , Edited by admin on Fri Dec 16 17:45:58 UTC 2022

PRIMARY

WIKIPEDIA

LATANOPROST

Created by admin on Fri Dec 16 17:45:59 UTC 2022 , Edited by admin on Fri Dec 16 17:45:59 UTC 2022

PRIMARY

CAS

130209-82-4

Created by admin on Fri Dec 16 17:45:58 UTC 2022 , Edited by admin on Fri Dec 16 17:45:58 UTC 2022

PRIMARY

DRUG CENTRAL

1551

Created by admin on Fri Dec 16 17:45:58 UTC 2022 , Edited by admin on Fri Dec 16 17:45:58 UTC 2022

PRIMARY

EVMPD

SUB08409MIG

Created by admin on Fri Dec 16 17:45:58 UTC 2022 , Edited by admin on Fri Dec 16 17:45:58 UTC 2022

PRIMARY

FDA UNII

6Z5B6HVF6O

Created by admin on Fri Dec 16 17:45:58 UTC 2022 , Edited by admin on Fri Dec 16 17:45:58 UTC 2022

PRIMARY

RS_ITEM_NUM

1357475

Created by admin on Fri Dec 16 17:45:59 UTC 2022 , Edited by admin on Fri Dec 16 17:45:59 UTC 2022

PRIMARY

DRUG BANK

DB00654

Created by admin on Fri Dec 16 17:45:58 UTC 2022 , Edited by admin on Fri Dec 16 17:45:58 UTC 2022

PRIMARY

RXCUI

43611

Created by admin on Fri Dec 16 17:45:59 UTC 2022 , Edited by admin on Fri Dec 16 17:45:59 UTC 2022

PRIMARY

RxNorm

IUPHAR

1961

Created by admin on Fri Dec 16 17:45:58 UTC 2022 , Edited by admin on Fri Dec 16 17:45:58 UTC 2022

PRIMARY

PUBCHEM

5311221

Created by admin on Fri Dec 16 17:45:59 UTC 2022 , Edited by admin on Fri Dec 16 17:45:59 UTC 2022

PRIMARY

MERCK INDEX

M6701

Created by admin on Fri Dec 16 17:45:58 UTC 2022 , Edited by admin on Fri Dec 16 17:45:58 UTC 2022

PRIMARY

Merck Index

Related Record Type Details


					I6393O0922

LATANOPROSTENE BUNOD

PARENT -> METABOLITE


					HVJ5726QJO

1,2,3,4-TETRANOR LATANOPROST ACID, LACTONE-

METABOLITE -> PARENT

Comments:

There is an equilibrium between the acid and the lactone

Interaction Type:

MAJOR

Qualification:

FECAL; URINE


					65SZ481V2C

1,2-DINOR LATANOPROST ACID

METABOLITE -> PARENT

Interaction Type:

MAJOR

Qualification:

FECAL; URINE


					O732R24Q9W

1,2,3,4-TETRANOR LATANOPROST ACID

METABOLITE -> PARENT

Interaction Type:

MAJOR

Qualification:

FECAL; URINE

Related Record Type Details


					L52RSE5UMA

PROPAN-2-YL (5Z)-7-((1R,2R,3R,5S)-3-(FORMYLOXY)-5-HYDROXY-2-((3R)-3-HYDROXY-5-PHENYLPENTYL)CYCLOPENTYL)HEPT-5-ENOATE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					9GA4UB7HVR

PROPAN-2-YL (5Z)-7-((1R,2R,3R,5S)-5-(FORMYLOXY)-3-HYDROXY-2-((3R)-3-HYDROXY-5-PHENYLPENTYL)CYCLOPENTYL)HEPT-5-ENOATE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					8BE5N693FM

PROPAN-2-YL (5Z)-7-((1R,2R,3R,5S)-2-((3R)-3-(FORMYLOXY)-5-PHENYLPENTYL)-3,5-DIHYDROXYCYCLOPENTYL)HEPT-5-ENOATE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					453JL3QHE4

ISOPROPYL 5-(DIPHENYLPHOSPHORYL)PENTANOATE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					P2MHT3VQ4F

LATANOPROST TRIS(TRIETHYLSILYL) ETHER

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					EJ85341990

LATANOPROST ACID

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					P840K2J2DL

LATANOPROST, (15S)-

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					ZC39I2T1VW

LATANOPROST, (5E)-

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					5TJW3B4DLT

LATANOPROST METHYL ESTER

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:

Related Record Type Details


					EJ85341990

LATANOPROST ACID

ACTIVE MOIETY

Amount:

Details

SMILES

InChI

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

C_max

T_1/2

Drug as perpetrator